15 October 2021
Consilium Strategic Communications advised Jeito Capital on the closing of its first fund, Jeito I at €534 million ($630 million)
London, 15 October 2021, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is proud to have supported Jeito Capital, on the final closing of its first fund at €534 million ($630 million), exceeding its original target of €500 million.
Jeito Capital is a rapidly growing, independent Private Equity firm dedicated to biotech and biopharma. Its first fund, Jeito I, is the largest European fund dedicated to supporting companies in the life sciences sector. The Company is building a strong and diversified portfolio of biotech and biopharma companies primarily based in Europe with global reach, focused on the treatment of life-threatening diseases. Jeito’s unique investment model provides support to entrepreneurs by a multi-talented team of experts integrated into the investment team across the entire drug development value chain, from translational science to market access and commercialization, with significant capital in continuity, up to €80 million ($100 million) in a single company.
Jeito I investments to date include French-based SparingVision and InnoSkel, in the fields of genomic ophthalmology and rare skeletal disorders, respectively, Dutch biotech Neogene Therapeutics in solid tumors, UK-based Pulmocide in severe respiratory diseases, and Swiss-French Alentis Therapeutics in fibrosis and related cancers.
“Throughout our time working with Jeito Capital, we have enjoyed seeing the firm rapidly grow and expand its impact in European biotech. This latest fund closing is a testament to not only Jeito’s unique investment model, but the incredibly hard work of the entire Jeito team. We would like to congratulate Rafaèle and the team at Jeito on this successful fundraise and we look forward to continuing to work with them as they innovate and invest to make a difference for patients and other key stakeholders within the life sciences sector.”
Mary-Jane ElliottManaging Partner of Consilium Strategic Communications
“The closing of Jeito I is an extremely proud achievement for Jeito, and we are delighted to have exceeded our target, making the fund the largest of its kind dedicated to the life sciences sector. I would like to thank the professional team at Consilium for their strategic advice and support.”
Dr. Rafaèle TordjmanFounder and CEO of Jeito Capital
The Consilium team representing Jeito Capital on the fund closing was Mary-Jane Elliott, Allison Connolly, Melissa Gardiner, Davide Salvi, Kris Lam and Lucie Foster.
To view Jeito Capital’s announcement please visit www.jeito.life
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. Consilium's team, based in both Europe and US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision makers and executives on critical communications programmes, international media management, transactions and healthcare stakeholder challenges. Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to
discrete specialist reputation management projects. For more information please see www.consilium-comms.com
About Jeito Capital
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe & the United States. Jeito Capital has €534 million under management. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit www.jeito.life, or follow on Twitter @Jeito_life or LinkedIn.